Claims for Patent: 5,376,645

Summary for Patent: 5,376,645

Title:	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
Abstract:	Sulfoalkyl ether cyclodextrin derivatives and their use as solubilizing agents for water insoluble drugs for oral, intranasal, or parenteral administration are disclosed.
Inventor(s):	Valentino J. Stella, Roger Rajewski
Assignee:	UNIVERSDITY OF KANSAS , University of Kansas
Application Number:	US07/918,702
Patent Claims:	1. A cyclodextrin derivative composition which comprises a cyclodextrin derivative of formula ##STR3## wherein: n is 4, 5 or 6;R1, R2, R3, R4, R5, R6, R7, R8 and R9 are each, independently, O- or a O-(C2-6 alkylene)-SO3 - group, and at least one of R1 and R2 is, independently, said O-(C2-6 alkylene)-SO3 - group; and S1, S2, S3, S.sub.4, S5, S6, S7, S8 and S9 are each, independently, a pharmaceutically acceptable cation, and wherein said composition contains less than about 50% of underivatized cyclodextrin. 2. The composition of claim 1, wherein R1, R2 and R3 are each, independently, said O-(C2-6 alkylene)-SO3 - group. 3. The composition of claim 1, wherein R1, R2 and R3 are each, independently a O-(CH2)m -SO3 - group, wherein m is 3 or 4. 4. The composition of claim 1, wherein:at least one of R4, R6 and R8 is, independently, said O-(C2-6 -alkylene)-SO3 - group; and R5, R7, and R9 are all O-. 5. The composition of claim 2, wherein:at least one of R4, R6 and R8 is, independently, said O-(C2-6 -alkylene)-SO3 - group; and R5, R7, and R9 are all O-. 6. The composition of claim 2, wherein:R4, R6 and R8 are each a O-(C2-6 alkylene)-SO3 - group; and R5, R7, and R9 are all O-. 7. The composition according to claim 1, wherein n is 5. 8. The composition according to claim 7, wherein said C2-6 alkylene is a C3 alkylene. 9. The composition according to claim 7, wherein said C2-6 is a C4 alkylene. 10. The composition according to claim 8, wherein said cyclodextrin derivatives in said composition contain an average of about one O-(C2 -C6 alkylene)-SO3 - group per cyclodextrin molecule. 11. The composition according to claim 8, wherein said cyclodextrin derivatives in said composition contain an average of about 3.6 O-(C2 -C6 alkylene)-SO3 - group per cyclodextrin molecule. 12. The composition according to claim 8, wherein said cyclodextrin derivatives in said composition contain an average of about 7 O-(C2 -C6 alkylene) -SO3 - group per cyclodextrin molecule. 13. The composition according to claim 9, wherein said cyclodextrin derivatives in said composition contain an average of about one O-(C2 -C6 alkylene)-SO3 - group per cyclodextrin molecule. 14. The composition according to claim 9, wherein said cyclodextrin derivatives in said composition contain an average of about 4.7 O-(C2 -C6 alkylene)-SO3 - group per cyclodextrin molecule. 15. The composition according to claim 9, wherein said cyclodextrin derivatives in said composition contain an average of about 7 O-(C2 -C6 alkylene)-SO3 - group per cyclodextrin molecule. 16. The composition according to claim 1, wherein said composition contains less than 40% underivatized cyclodextrin. 17. The composition according to claim 7, wherein said composition contains less than 40% underivatized cyclodextrin. 18. The composition according to claim 8, wherein said composition contains less than 40% β-cyclodextrin. 19. The composition according to claim 9, wherein said composition contains less than 40% β-cyclodextrin. 20. The composition according to claim 16, wherein said composition contains less than 25% β-cyclodextrin. 21. The composition according to claim 17, wherein said composition contains less than 25% underivatized cyclodextrin. 22. The composition according to claim 8, wherein said composition contains less than 25% underivatized cyclodextrin. 23. The composition according to claim 9, wherein said composition contains less than 25% β-cyclodextrin. 24. A composition comprising a drug complexed to a cyclodextrin derivative of formula (2): ##STR4## wherein: n is 4, 5 or 6;R1, R2, R3, R4, R5, R6, R7, R8 and R9 are each independently O- or a O-(C2-6 alkylene)-SO3 - group, and at least one of R1 and R2 is, independently, said O-(C2-6 alkylene)-SO3 - group; and S1 to S9 are each, independently, a pharmaceutically acceptable cation; wherein said composition contains not more than about 50 wt. % of underivatized cyclodextrin. 25. The composition of claim 24, wherein R1, R2 and R3 are each, independently, said O-(C2-6 alkylene)-S3 - group. 26. The composition of claim 24, wherein:at least one of R4, R6 and R8 is, independently, said O-(C2-6 -alkylene)-SO3 - group; and R5, R7, and R9 are all O-. 27. The composition of claim 25, wherein:at least one of R4, R6 and R8 is, independently, said O-(C2-6 -alkylene)-SO3 - group; and R5, R7 , and R9 are all O-. 28. The composition of claim 27, wherein R4, R6 and R8 are each, independently, said O-(C2-6 alkylene)-SO3 - group. 29. The composition of claim 24, wherein said drug is one member selected from the group consisting of amobarbital, ampicillin, aspirin, beclomethasone, benzocaine, benzodiazepines, betamethasone, chlorambucil, chloramphenicol, chlorpromazine, clofibrate, coenzyme A, cortisone, cortisone acetate, cyclobarbital, dexamethasone, dexamethasone acetate, diazepam, digitoxin, digoxin, estradiol, 5-fluorouracil, flurbiprofen, griseofulvin, hydrocortisone, hydrocortisone acetate, ibuprofen, indomethanin, ketoprofen, methicillin, metronidazole, mitomycin, nitrazepam, nitroglycerin, penicillin, pentobarbital, phenobarbital, phenobarbitone, phenyltoin, prednisolone, prednisolone acetate, progesterone, prostaglandin A series, prostaglandin B series, prostaglandin E series, prostaglandin F series, reserpine, sulfaceatamide sodium, testosterone, vitamin A, vitamin D3, vitamin E, vitamin K3, and warfarin. 30. The composition according to claim 24, wherein n is 5. 31. The composition according to claim 30, wherein said C2-6 alkylene is a C3 alkylene. 32. The composition according to claim 30, wherein said C2-6 is a C4 alkylene. 33. The composition according to claim 31, wherein said cyclodextrin derivatives in said composition contain an average of about 1, 3.6 or 7 O-(C2 -C6 alkylene)-SO3 - groups per cyclodextrin molecule. 34. The composition according to claim 32, wherein said cyclodextrin derivatives in said composition contain an average of about 1, 4.7 or 7 O-(C2 -C6 alkylene)-SO3 - groups per cyclodextrin molecule. 35. The composition according to claim 24, wherein said composition contains less than 40% β-cyclodextrin. 36. The composition according to claim 30, wherein said composition contains less than 40% β-cyclodextrin. 37. The composition according to claim 31, wherein said composition contains less than 40% β-cyclodextrin. 38. The composition according to claim 32, wherein said composition contains less than 40% β-cyclodextrin. 39. The composition according to claim 33 wherein said composition contains less than 40% β-cyclodextrin. 40. The composition according to claim 34, wherein said composition contains less than 40% β-cyclodextrin. 41. The composition according to claim 35, wherein said composition contains less than 25% β-cyclodextrin. 42. The composition according to claim 36, wherein said composition contains less than 25% β-cyclodextrin. 43. The composition according to claim 37, wherein said composition contains less than 25% β-cyclodextrin. 44. The composition according to claim 38, wherein said composition contains less than 25% β-cyclodextrin. 45. The composition according to claim 39, wherein said composition contains less than 25% β-cyclodextrin. 46. The composition according to claim 40 wherein said composition contains less than 25% β-cyclodextrin. 47. A pharmaceutical composition for oral administration comprising a pharmaceutically, orally suitable carrier and a clathrate complex comprising a drug complexed to a cyclodextrin derivative of formula (2): ##STR5## wherein: n is 4, 5 or 6;R1, R2, R3, R4, R5, R6, R7, R8 and R9 are each independently O- or a O-(C2-6 alkylene)-SO3 - group, and at least one of R1 and R2 is, independently, said O-(C2-6 alkylene)-SO3 - group; and S1 to S9 are each, independently, a pharmaceutically acceptable cation;wherein said composition contains not more than 50 wt. % of underivatized cyclodextrin.